Table 2.

Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile for population, intervention, comparison, outcome 17: Molnupiravir for mild or moderate coronavirus disease 2019^a

People: Patients with mild or moderate COVID-19, risk factors for progressive disease, and <5 d of on-going symptoms. Settings: Ambulatory patients Intervention: Molnupiravir at 800 mg administered orally, twice daily for 5 d Comparison: Placebo
Outcomes	Absolute effect		Relative effect (95% CI)	Number of studies	Certainty of the evidence (GRADE)
	With molnupiravir	Without molnupiravir
All-cause admissions or death (within 29 d from treatment)	48/709 (6.8%)	68/699 (9.7%)	RR: 0.70 (0.49–0.99)	1 [27] (1433 patients)	⊕⊕⊕⊖ Moderate (serious imprecision: all patients included were not vaccinated; there were no differences in the sub-group of patients with SARS-CoV-2 IgG)
	Difference: 3 fewer per 100 (95% CI: −5.9 to −0.1)
Serious adverse events	49/710 (6.9%)	67 (9.6%)
	Non-significant differences (95% CI: −7.4 to 2.3)

COVID-19, coronavirus disease 2019; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RR, risk ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^aEvidence adopted: Evidence adopted: Australian Guideline for clinical care of patients with COVID-19 at https://app.magicapp.org/#/guideline/6268/section/101962 accessed March–April 2022. Evidence search date: March 2022.